Clinical Trial

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Study acronym: Krascendo 2
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the efficacy and safety of divarasib and pembrolizumab compared with pembrolizumab and pemetrexed and carboplatin or cisplatin, for the first-line treatment of adult participants with KRAS G12C-mutated, advanced or metastatic non squamous non-small cell lung cancer (NSCLC).
Protocol Amendment History 5 changes
notable Trial sites expanded: 260 -> 268 locations 2026-08-07
notable Trial sites expanded: 251 -> 260 locations 2026-07-08
notable Trial sites expanded: 240 -> 251 locations 2026-06-10
notable Trial sites expanded: 217 -> 240 locations 2026-05-12
notable Trial sites expanded: 195 -> 217 locations 2026-04-14
Trial Details
NCT Number NCT06793215
Lead Sponsor Hoffmann-La Roche
Collaborators: Chugai Pharmaceutical
Conditions Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
Enrollment 600 participants
Start Date 2025-10-24
Primary Completion 2028-11-30 (estimated)
Study Completion 2030-10-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-06